Avid Bioservices Inc (CDMO)

[biopharm]

I received a couple messages that the PS Targeting - New England Peptide company video if it does not auto play or signed in ...just do a search for "Sam Massoni exosomes"

Answers must be given to shareholders ...it is and always was about the IP assets and since flipped PS exists on all stressed cells leading to inflammation leading to diseased cells leading to cancer, then that is the Targeting of CDMO IP assets

Ampersand Capital that now controls Avid CDMO BOD, it seems....is not being truthful and if they are aligned with John Springs Stafford, one better learn to complain loud and clear

______

October 8, 2019
Wellesley equity firm buys majority of Gardner biotech

Sam Massoni, president and CEO of New England Peptide
By Sam Bonacci
Gardner biomanufacturer New England Peptide has received a majority recapitalization from Wellesley private equity firm Ampersand Capital Partners, as the company sets its sights on continued expansion.

New England Peptide designs and manufactures peptide and antibody solutions for drug, vaccine and diagnostic development organizations worldwide. The investment will be used to support the company's worldwide growth initiatives, according to Ampersand, including expanding peptide synthesis capabilities.

The amount of Ampersand's investment was not disclosed.

Ampersand is a middle market private equity firm focused on growth-oriented investments in the healthcare sector with offices in Greater Boston and Amsterdam, Netherlands.

As part of the transaction, José de Chastonay will become the executive chairman of the company's board of directors. He has served in a number of senior management and advisory roles within various research chemical manufacturing organizations, most recently as chief marketing officer and Member of the corporate executive committee at Swiss technology company Bachem Holding AG.

New England Peptide CEO and Founder Sam Massoni said in a statement he was excited to partner with de Chastonay and move forward with assistance from Ampersand.

https://www.wbjournal.com/article/wellesley-equity-firm-buys-majority-of-gardner-biotech